During the past decade, University of Tsukuba Hospital conducted 36 clinical trials. In the 10-year time frame, 36 clinical trials started and 13 clinical trials were completed, i.e. on average, 36.1% percent of trials that started reached the finish line to date. In the past 5 years, 21 clinical trials started and 11 clinical trials were completed. i.e. 52.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Tsukuba Hospital" #1 sponsor was "Hoffmann-La Roche" with 9 trials, followed by "Eli Lilly and Company" with 5 trials sponsored, "Janssen Research & Development, LLC" with 4 trials sponsored, "Actelion" with 3 trials sponsored and "AstraZeneca" with 3 trials sponsored. Other sponsors include 19 different institutions and companies that sponsored additional 25 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Tsukuba Hospital" #1 collaborator was "Chugai Pharmaceutical" with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Alliance Foundation Trials (AFT)" with 1 trials as a collaborator, "Arbeitsgemeinschaft Gynaekologische Onkologie Austria" with 1 trials as a collaborator and "Arbeitsgemeinschaft Gynaekologishe Onkologie Germany" with 1 trials as a collaborator. Other collaborators include 17 different institutions and companies that were collaborators in the rest 27 trials.

According to Clinical.Site data, the most researched conditions in "University of Tsukuba Hospital" are "Breast Neoplasms" (3 trials), "Rheumatoid Arthritis" (3 trials), "Carcinoma, Renal Cell" (2 trials), "Epithelial Ovarian Cancer" (2 trials) and "Paroxysmal Nocturnal Hemoglobinuria" (2 trials). Many other conditions were trialed in "University of Tsukuba Hospital" in a lesser frequency.

Most popular intervention types in "University of Tsukuba Hospital" are "Drug" (44 trials), "Other" (5 trials), "Biological" (2 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (16 trials), "Atezolizumab" (6 trials), "Abemaciclib" (3 trials), "Exemestane" (3 trials) and "Crovalimab" (2 trials). Other intervention names were less common.

The vast majority of trials in "University of Tsukuba Hospital" are 41 trials for "All" genders, 5 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "University of Tsukuba Hospital". undefined are not yet recruiting, 12 are recruiting, 13 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 20 completed trials in University of Tsukuba Hospital, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in University of Tsukuba Hospital, 0 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 35 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".